Get started
Author

Olivier Marcq

Institution: Tubulis (Germany)
ORCID: 0000-0001-9097-7146
Observed ORCID: 0000-0001-9097-7146
OpenAlex ID: A5094219282
Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation
2016 · Jianxin Guo, Sandeep Kumar, et al. · Bioconjugate Chemistry · 86
Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development
2019 · Fikri Avci, Francesco Berti, et al. · mSphere · 50
Reaction pathways of glucose oxidation by ozone under acidic conditions
2009 · Olivier Marcq, Jean-Michel Barbe, et al. · Carbohydrate Research · 37
NMR structural analysis of the capsular polysaccharide from Streptococcus pneumoniae serotype 6C
2012 · Ping Cai, Justin Moran, et al. · Carbohydrate Research · 18
Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates
2026 · Philipp Ochtrop, Anil P. Jagtap, et al. · Nature Communications · 9
PDF
Origin and significance of the production of carbon dioxide during the ozonization of 13C-labeled d-glucose at different pH values
2001 · Olivier Marcq, Jean-Michel Barbe, et al. · Carbohydrate Research · 9
TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al. · Molecular Cancer Therapeutics · 7
PDF
Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans
2024 · Saskia Schmitt, Isabelle Mai, et al. · Cancer Research · 7
Addition of Lauryldimethylamine N-Oxide (LDAO) to a Copper-Free Click Chemistry Reaction Improves the Conjugation Efficiency of a Cell-Free Generated CRM197 Variant to Clinically Important Streptococcus pneumoniae Serotypes
2022 · Leslie Bautista, Lucy Pill-Pepe, et al. · ACS Omega · 7
PDF
1047. Development of a Next Generation 30+ Valent Pneumococcal Conjugate Vaccine (VAX-XP) Using Site-Specific Carrier Protein Conjugation
2021 · Chris Behrens, Jeff Fairman, et al. · Open Forum Infectious Diseases · 4
Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index
2024 · Saskia Schmitt, Isabelle Mai, et al. · Cancer Research · 3
Supplementary Table 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Table 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 10 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 5 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 4 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 6 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 3 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 7 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Methods 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 8 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 9 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Data from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Works count: 25
Citation count: 237
H-index: 7
I10-index: 4
Year
Topic
Type